Eli Lilly reports 23.3% average weight loss with amylin-Zepbound combo in diabetic obesity trial
In a phase-2 study, Eli Lilly's amylin-Zepbound combination achieved a 23.3% average weight loss and improved A1C in adults with obesity or overweight and type-2 diabetes, prompting plans for phase-3 trials.
Eli Lilly said its experimental combination of the amylin receptor agonist eloralintide and the approved GIP/GLP-1 drug Zepbound (tirzepatide) produced an average 23.3% weight loss in a phase-2 trial of 367 adults with obesity or overweight and type-2 diabetes. At the highest dose, participants lost an average of 54.1 pounds after 48 weeks and showed reductions in A1C.
The study compared several dose levels of the combination, each component alone, and placebo. Eloralintide 9 mg with Zepbound 15 mg yielded the greatest weight loss, while eloralintide 6 mg alone resulted in an average loss of 28.6 pounds and Zepbound 15 mg alone produced a 34.4-pound average loss.
"Obesity and type 2 diabetes are interconnected, and we are seeing the potential benefit of targeting multiple hormonal pathways to address both," said Dr. Liana K. Billings, director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health and lead author of the study.
The company plans to start phase-3 trials of the combination in the fourth quarter of 2026. Analysts noted that the 23.3% average loss is comparable to tirzepatide results in patients without diabetes and exceeds a 17% benchmark often cited for efficacy.
Safety data showed a higher incidence of gastrointestinal adverse events in the combination arm, with up to 27% of participants discontinuing treatment. Analysts suggested that staggered initiation of the two drugs in future trials could improve tolerability while maintaining efficacy.
Lilly's findings were presented at the 62nd annual meeting of the European Association for the Study of Diabetes in Milan, alongside other metabolic-drug updates, including data from Zealand Pharma on its amylin analog petrelintide.